As Directors of the University of Washington?s Teratogen Information System (TERIS), we are writing to you about an academic resource that is widely used by obstetricians and healthcare professionals who treat pregnant women in their clinical practices. TERIS is an electronic database that summarizes available clinical, epidemiological, and experimental data on the teratogenic risks of over 1,750 medications and other agents such as viruses and vaccines. We recently added reports on the medications being used to treat COVID-19 and the vertical transmission of the SARS-CoV-2 virus.


Founded in 1984 by Dr. Jan Friedman M.D., Ph.D., a globally respected clinical geneticist, TERIS is used to facilitate clinical decision making on the fetal risks of medications and other exposures during pregnancy and to guide patient counseling. The level of authoritative guidance that TERIS provides is unique. Each agent summary includes a teratogenic risk rating that is derived by consensus from the TERIS Advisory Board. The TERIS Advisory Board is composed of eight world-renowned experts in clinical teratology from the fields of medicine, epidemiology, and genetics.


Because TERIS is housed on an electronic platform, users of TERIS can login from any location with an internet connection to learn more about the risks of specific medications during pregnancy. We have had particularly good success in rural clinics and medically underserved areas where specialized resources may not be readily available. The cost to subscribe to TERIS is reasonable and offers the ability to distribute the resource to clinics across the country.


You may wish to learn more about TERIS or see examples of an agent summary through our website at the following link, The Teratogen Information System - TERIS.